Rapid Onsite Evaluation for Lung Nodules

(ARTEMIS Trial)

Not yet recruiting at 7 trial locations
SA
RP
Overseen ByRafael Paez Co-PI, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Vanderbilt University Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

ARTEMIS is a multicenter randomized controlled trial. The goal is to understand whether rapid onsite evaluation during robotic assisted bronchoscopy improves the diagnostic performance of the procedure or not.

Who Is on the Research Team?

FM

Fabien Maldonado, MD

Principal Investigator

Vanderbilt University Medical Center

Are You a Good Fit for This Trial?

This trial is for people who have lung nodules and are being considered for a minimally invasive diagnostic procedure using robotic bronchoscopy. Specific inclusion or exclusion criteria were not provided.

Inclusion Criteria

I am having a robotic bronchoscopy to biopsy a lung lesion.
I am at least 18 years old.

Exclusion Criteria

Pregnant or incarcerated patients
Patient previously consented for this trial
I am unable or unwilling to give my consent to join the study.
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • Rapid onsite evaluation

Trial Overview

The study compares two approaches to diagnosing lung nodules: one group gets rapid onsite evaluation during robotic-assisted bronchoscopy, while the other does not. The aim is to see if this improves diagnosis accuracy.

How Is the Trial Designed?

2

Treatment groups

Active Control

Group I: Robotic assisted bronchoscopy with ROSEActive Control1 Intervention
Group II: Robotic assisted bronchoscopy without ROSEActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vanderbilt University Medical Center

Lead Sponsor

Trials
922
Recruited
939,000+

AstraZeneca

Industry Sponsor

Trials
4,491
Recruited
290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology